Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31)

2.2 / 5 stars · 48/110 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31)

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31) of $424.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-18.

Discontinued › Notes › Segment Reporting

us-gaap:SegmentReportingInformationExpendituresForAdditionsToLongLivedAssets · last filed 2011-02-18

  • BRISTOL-MYERS SQUIBB COMPANY segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2010 was $424.00M, a 33.12% decline from fiscal 2009.
  • BRISTOL-MYERS SQUIBB COMPANY segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2009 was $634.00M, a 7.58% decline from fiscal 2008.
  • BRISTOL-MYERS SQUIBB COMPANY segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2008 was $686.00M.
Period endSegment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31) 12 month
2010-12-31$424.00M
10-K · filed 2011-02-18
2009-12-31$634.00M
10-K · filed 2011-02-18
2008-12-31$686.00M
10-K · filed 2011-02-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64